Abstract
Progressive supranuclear palsy (PSP) is a severe neurodegenerative disease still lacking of alleviating treatments for either cognitive or motor disturbances. Aimed at widening the spectrum of therapeutic options, here, we describe efficacy and safety of a long-term treatment with Rotigotine, a non-ergolinic dopamine agonist, in PSP. Seven PSP drug-naïve patients, presenting with Richardson’s syndrome, received up to 6 mg/24 h transdermal patch for 42 weeks as unique therapy. Adverse effects were recorded; efficacy was measured by comparing baseline and final treatment scores of Montreal Cognitive Assessment (MoCA), Unified Parkinson Disease Rating Scale part3, and PSP rating scale (PSP-RS). At the end of our observation, no significant adverse events occurred; the cognitive item of PSP-RS was improved and MoCA score was similar at baseline. Contrariwise, motor disturbances worsened according to disease progression. Our observation thus suggests that long-term treatment with low doses of rotigotine is well tolerated and may support cognitive functions of PSP patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Litvan I, Kong M (2014) Rate of decline in progressive supranuclear palsy. Mov Disord 29:463–468. https://doi.org/10.1002/mds.25843
Schirinzi T, Di Lazzaro G, Colona VL et al (2017) Assessment of serum uric acid as risk factor for tauopathies. J Neural Transm. https://doi.org/10.1007/s00702-017-1743-6
Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270–279. https://doi.org/10.1016/S1474-4422(09)70042-0
Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018) Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm. https://doi.org/10.1007/s00702-018-1893-1
Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766. https://doi.org/10.1002/mds.26054
Schirinzi T, Sancesario GM, Ialongo C et al (2015) A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus. Front Neurol 6:86. https://doi.org/10.3389/fneur.2015.00086
Lamb R, Rohrer JD, Lees AJ, Morris HR (2016) Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol 18:42. https://doi.org/10.1007/s11940-016-0422-5
Constantinescu R, Richard I, Kurlan R (2007) Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 22:2141–2148. https://doi.org/10.1002/mds.21578
Nuebling G, Hensler M, Paul S et al (2016) PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol 263:1565–1574. https://doi.org/10.1007/s00415-016-8169-1
Eschlböck S, Krismer F, Wenning GK (2016) Interventional trials in atypical parkinsonism. Parkinsonism Relat Disord 22(Suppl 1):S82–S92. https://doi.org/10.1016/j.parkreldis.2015.09.038
Murphy KE, Karaconji T, Hardman CD, Halliday GM (2008) Excessive dopamine neuron loss in progressive supranuclear palsy. Mov Disord 23:607–610. https://doi.org/10.1002/mds.21907
Elshoff J-P, Braun M, Andreas J-O et al (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34:966–978. https://doi.org/10.1016/j.clinthera.2012.02.008
Ray Chaudhuri K, Martinez-Martin P, Antonini A et al (2013) Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 19:660–665. https://doi.org/10.1016/j.parkreldis.2013.02.018
Schirinzi T, Imbriani P, Elia AD et al (2017) Rotigotine may control drooling in patients with Parkinson’ s disease: preliminary findings. Clin Neurol Neurosurg 156:63–65. https://doi.org/10.1016/j.clineuro.2017.03.012
Moretti DV, Binetti G, Zanetti O, Frisoni GB (2014) Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism. Front Neurol 5:85. https://doi.org/10.3389/fneur.2014.00085
Moccia M, Picillo M, Erro R et al (2015) Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy. J Neurol Sci 350:103–104. https://doi.org/10.1016/j.jns.2015.01.025
Moretti DV, Binetti G, Zanetti O, Frisoni GB (2014) Rotigotine is safe and efficacious in atypical Parkinsonism syndromes induced by both α-synucleinopathy and tauopathy. Neuropsychiatr Dis Treat 10:1003–1009. https://doi.org/10.2147/NDT.S64015
Litvan I, Agid Y, Jankovic J et al (1996) Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 46:922–930
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864. https://doi.org/10.1002/mds.26987
Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130:1552–1565
Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745. https://doi.org/10.1212/WNL.0b013e3181c34b47
Fiorenzato E, Weis L, Falup-Pecurariu C et al (2016) Montreal cognitive assessment (MoCA) and mini-mental state examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. J Neural Transm 123:1435–1442. https://doi.org/10.1007/s00702-016-1589-3
Golbe LI (2014) Progressive supranuclear palsy. Semin Neurol 34:151–159. https://doi.org/10.1055/s-0034-1381736
Lagarde J, Valabrègue R, Corvol JC et al (2013) Are frontal cognitive and atrophy patterns different in PSP and bvFTD? A comparative neuropsychological and VBM study. PLoS One 8:1–10. https://doi.org/10.1371/journal.pone.0080353
Brenneis C, Seppi K, Schocke M et al (2004) Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75:246–249
Ott T, Nieder A (2016) Dopamine D2 receptors enhance population dynamics in primate prefrontal working memory circuits. Cereb Cortex. https://doi.org/10.1093/cercor/bhw244
Martorana A, Di Lorenzo F, Esposito Z et al (2013) Dopamine D2-agonist Rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients. Neuropharmacology 64:108–113. https://doi.org/10.1016/j.neuropharm.2012.07.015
Schirinzi T, Madeo G, Martella G et al (2016) Early synaptic dysfunction in Parkinson’s disease: insights from animal models. Mov Disord 31:802–813. https://doi.org/10.1002/mds.26620
Funding
No funding has been received for this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Ethical standards
The study was conducted according with institutional ethical standards and the Helsinki declaration.
Informed consent
All participants signed an informed consent.
Rights and permissions
About this article
Cite this article
Schirinzi, T., Pisani, V., Imbriani, P. et al. Long-term treatment with rotigotine in drug-naïve PSP patients. Acta Neurol Belg 119, 113–116 (2019). https://doi.org/10.1007/s13760-018-0993-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-018-0993-x